Introducton

So many clinical trials of positive inotropes have failed, that it is now axiomatic that agents that increase cAMP are deleterious to the failing heart. An alternative strategy is to alter myocardial Ca\(^{2+}\) handling or myofilament response to Ca\(^{2+}\) using agents that do not affect cAMP. Although left ventricular (LV) function is tightly linked to adenyl cyclase (AC) activity, the beneficial effects of AC may be independent of cAMP and instead stem from effects on Ca\(^{2+}\) handling. Here we ask whether an AC mutant molecule that reduces LV cAMP production would have favorable effects on LV function through its effects on Ca\(^{2+}\) handling alone.

Methods and Results: We generated transgenic mice with cardiac-directed expression of an AC6 mutant (AC6mut). Cardiac myocytes showed impaired cAMP production in response to isoproterenol (74% reduction; p<0.001), but LV size and function were normal. Isolated hearts showed preserved LV function in response to isoproterenol stimulation. AC6mut expression was associated with increased sarcoplasmic reticulum Ca\(^{2+}\) uptake and the EC_{50} for SERCA2a activation was reduced. Cardiac myocytes isolated from AC6mut mice showed increased amplitude of Ca\(^{2+}\) transients in response to isoproterenol (p = 0.0001). AC6mut expression also was associated with increased expression of LV S100A1 (p = 0.03) and reduced expression of phospholamban protein (p = 0.01).

Conclusion: LV AC mutant expression is associated with normal cardiac function despite impaired cAMP generation. The mechanism appears to be through effects on Ca\(^{2+}\) handling — effects that occur despite diminished cAMP.

Data from previous studies indicate that increased cardiac AC type 6 (AC6), a dominant AC isoform expressed in mammalian cardiac myocytes [6], has protein beneficial effects on the failing left ventricle (LV) [7],[8],[9],[10],[11],[12]. These unexpected beneficial effects must be reconciled with the dire consequences on the heart of BAR stimulation and elevations in intracellular cAMP [13],[14],[15],[16],[17],[18]. Indeed, the apparent benefits of AC6 expression in the failing heart is paradoxical. Using pharmacological inhibitors, data from previous studies suggest that some of the beneficial effects of increased cardiac AC6 expression do not depend upon increased cAMP generation [2],[3]. Because of the inherent limitations of studies using pharmacological inhibition in cultured cardiac myocytes, we generated a catalytically inactive AC6 mutant (AC6mut) molecule by substitution of Ala for Asp at position 426 in the catalytic core, a change predicted to alter Mg\(^{2+}\) binding but not influence G-protein dynamics [4]. This AC6mut molecule, when studied in vitro, markedly impairs cAMP generation, but retains the cellular distribution pattern associated with AC6 [4]. Such *in vitro* studies fall far short of establishing how such a molecule might influence cardiac function in vivo.
We therefore generated transgenic murine lines with cardiac-directed expression of AC6mut. Our hope was that such lines would provide additional insight vis-à-vis differentiation of cAMP vs Ca\textsuperscript{2+} handling effects on the function of the intact normal heart. Furthermore, such studies might indicate whether AC6mut provides inotropic stimulation free from the potentially deleterious effects of increased cAMP. Our hypothesis was that LV function, despite marked diminution in cAMP generating capacity, would remain normal, through beneficial counterbalancing effects conferred by AC6 on Ca\textsuperscript{2+} handling.

Methods

Generation of AC6mut Transgenic Mice (Fig. 1A)
The use of animals was in accordance with Association for Assessment and Accreditation of Laboratory Animal Care guidelines and was approved by the Institutional Animal Care and Use Committee of VA San Diego Healthcare System. To generate mice with cardiac-directed expression of AC6mut, the murine AC6mut cDNA [4] with an AU1 tag at the C-terminus, was subcloned between the β-myosin heavy chain promoter and SV40 polyA. A 9.2-kb fragment containing the expression cassette was used for pronuclear injection, carried out in the transgenic mouse facility at University of California, San Diego (inbred C57BL/6). Founder mice were identified by polymerase chain reaction (PCR) of genomic DNA prepared from tail tips. The AC6mut gene was detected using a primer homologous to the z-MHC promoter (forward: 5' CACATAGAAGCCTAGCCCA-CCACC); the reverse primer was for the AC6 region (5' CAGAGGCCACTAACCATTGCCA). AC6mut mRNA was detected using the following primers: (forward: 5' TGGGCTCTACTCCTCTG; reverse: 5' TGGATG-TAACCTGGGTTC-CTG) enabling quantification of fold increase of AC6mut mRNA over endogenous AC6 mRNA. Endogenous AC6 mRNA was detected using primers homologous to its 3'-untranslated region (forward: 5' CAGATTTAGTGG-GACCTTGT; reverse: 5' TCTGCACTCAGACAAAGC). This 3' untranslated region was not present in the AC6mut cDNA, enabling quantification of endogenous AC6. Founder animals were crossbred with wild-type mice of the same strain, and selected animals were used for analysis of cardiac transgene expression. We documented variable transgene expression in independent lines and selected a line with a 17-fold increase in AC6mut protein expression vs endogenous AC6 for our studies. LV expression levels of AC types 2–9 were determined using quantitative RT-PCR as previously described [5].

Echocardiography
Anesthesia was induced with 5% isoflurane (at a flow rate of 1 L/min oxygen) and maintained with 1% isoflurane in oxygen. Images were obtained using a 16 L MHz linear probe and Sonos 5500\textsuperscript{®} echocardiograph system (Philips Medical Systems, Bothell, WA), as previously reported [7]. Data were acquired and analyzed without knowledge of group identity.

Isolated Perfused Hearts: LV Contractile Function
Cardiac function was assessed in isolated perfused hearts to assess LV contractile function in a manner unaffected by reflex
calcium uptake or anesthesia, as previously reported [7]. An intravenous balloon catheter was deployed to measure isovolumic LV pressure (LV end-diastolic pressure 10 mmHg; 1.7 mM ionized Ca$^{2+}$). Isoproterenol was delivered in bolus doses (from 0.1 nM to 300 nM) at five-minute intervals as LV pressure was recorded. Subsequently, the first derivative of the LV pressure (LV dP/dt) was derived and used as a surrogate of LV contractile function. Data were acquired and analyzed without knowledge of group identity.

**Calcium Uptake**

Initial rate of ATP-dependent sarcoplasmic reticulum (SR) Ca$^{2+}$ uptake in LV homogenates was measured by the modified Millipore filtration technique as described previously [11].

**Calcium Transient**

Cytosolic calcium transients were measured using Indo-1, as described previously [19]. Cardiac myocytes were plated onto laminin-coated glass cover slips and loaded with indo-1/AM (3 μM, Calbiochem, La Jolla CA) and dispersing agent, pluronic F-127 (0.02 mg/ml, Calbiochem, La Jolla CA) for 30 min. Following dye loading, cover slips were mounted in a superfusion chamber, rinsed to remove excess indo-1/AM, and mounted on a Nikon Diaphot epifluorescence microscope equipped with a 40× objective interfaced to a Photon Technologies photometry system (Birmingham NJ) with the excitation wavelength set to 365 nm via a monochromator. Fluorescence emission was split and directed to two photomultiplier tubes through 20-nm band-pass filters centered at 405 and 485 nm, respectively. The ratio F405/F485 was recorded from at least 20 cells per heart and for at least 3 heart preparations from each group. Diastolic and systolic intracellular Ca$^{2+}$ levels were obtained from the basal and maximal F405/F485 ratio per cycle, respectively.

**Cardiac Myocyte Isolation**

Cardiac myocyte isolation was performed as previously described [4].

**Cyclic AMP Measurement**

Isolated cardiac myocytes were stimulated with isoproterenol (10 μM, 10 min) or the water-soluble forskolin analog NKH477 (10 μM, 10 min), and then lysed (2.5% dodecyltrimethylammonium bromide, 0.05 M sodium acetate, pH 5.8, and 0.002% bovine serum albumin). Cyclic AMP was measured using the cAMP Biotrak Enzymeimmunoassay System (GE Healthcare) as previously reported [4].

**PKA Activity Assay**

Isolated cardiac myocytes were stimulated with isoproterenol (10 μM, 10 min) or NKH477 (10 μM, 10 min). Cardiac myocytes were homogenized in buffer A: 20 mM Tris-HCl (pH 7.5), 0.5 mM EGTA, 0.5 mM EDTA, and protease inhibitor cocktail from Invitrogen) and centrifuged (14,000 rpm, 15 min, 4°C). The supernatant was incubated with PKA biotinylated peptide substrate (SigmaTECT® cAMP-Dependent Protein Kinase Assay System, Promega, Madison WI) in the presence of [γ-32P]ATP. The 32P-labeled, biotinylated substrate was recovered with a streptavidin matrix, and the specific activity of PKA determined.

Isoproterenol-Stimulated Phosphorylation of Ryanodine Receptor-2, PLB, and Troponin I in Cardiac Myocytes

To determine dynamic phosphorylation of key Ca$^{2+}$ regulating proteins, we conducted studies of basal and isoproterenol-stimulated phosphorylation of RyR2, PLB and TnI in cultured cardiac myocytes isolated from each group (Fig. 2C). Cultured cardiac myocytes (100,000 cells per well) were used in these studies and immunoblotting performed before and after incubation with isoproterenol (10 μM, 10 min). Cells were lysed in lysis buffer: 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na$_2$EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na$_3$VO$_4$, 1 μg/ml leupeptin). Protein concentration was measured using the Bradford method. Immunoblots were normalized to GAPDH and compared (Fig. 2D).

**PDE Activity Assay**

Phosphodiesterase activity was assayed using the Cyclic Nucleotide Phosphodiesterase Assay Kit (Enzo). LV tissues were homogenized in buffer containing 10 mM Tris-HCl (pH 7.4), 1 mM PMSF, 10 mM activated orthovanadate, 1× protease inhibitor cocktail (Life Sciences) and centrifuged at 10,000 rpm (10 min) in a microfuge. Tissue homogenates were desalted by gel filtration using Desalting Column Resin (Enzo). Twenty μg of protein (Bradford) was added to each well and PDE activity measured.

**Immunofluorescence**

Isolated cardiac myocytes were attached to laminin coated 2-well chamber slides for 1 hr, washed, fixed (10% formalin, 15 min, 23°C), blocked with normal goat serum (1 hr) and incubated (4°C, overnight) with: anti-AU1 antibody (Fitzgerald, 1:300; for detecting AC6mut transgene protein); anti-Cav3 antibody (BD Pharmagen, 1:100; for detecting caveola); anti-PDI antibody (Invitrogen, 1:1000; for detecting SR); anti-lamin A (Abcam, 1:200; for detecting nuclear envelope); anti-CREM-1 antibody (Santa Cruz, 1:50); or anti-phospho-CREB antibody (Upstate, 1:100). Cardiac myocytes were washed with PBS and then incubated with secondary antibodies (Alexa Fluor 488 or 594 conjugated, 1:1000 dilution) for 1 hr. To identify the nucleus, cells were incubated with Hoechst dye (1:1000 dilution, 20 min). Cardiac myocytes then were imaged as previously described [2].

**Detection of mRNA and Immunoblotting**

Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to quantify mRNA and immunoblotting was used to quantify protein content [4]. The primers for RyR2 included (forward: 5’AACCTACCGAGCTTGGAATG; and reverse: 5’ GACCTCGATGGCAGAATC). We used the anti-AC5/6 antibody to identify endogenous AC6 and AC6mut (sequence: KGYQLECRGGVKKGKEMTFTLYNGLPSS; protein accession #O43306 and #Q9I234). We used AU1 antibody (Fitzgerald, 1:2000) to detect AC6mut protein. Additional antibodies used included: calreticulin (ABR Affinity, 1:1000); calcequin ([Novus Biologicals, 1:1000]; GAPDH (Fitzgerald, 1:20000); PDE3A (Santa Cruz, 1:500); PKA catalytic subunit (BD Transduction, 1:1000); p-PKA catalytic subunit (Cell Signaling, 1:1000); PKA-RIIβ and PKA-RIIβ (BD Transduction, 1:1000); phospho-PKA-RIIβ (S96) and phospho-PKA-RIIβ (S114) (Santa Cruz, 1:200); PKCx catalytic subunit (Santa Cruz, 1:200); PLB (Affinity Bioreagents, 1:5000); phospho S16-PLB (Badrilla, 1:3000 dilution); phospho-RyR2 (S2808) (Abcam, 1:1000).
1:1,000); S100A1 (Epiyomics, 1:1,000); SERCA2a (Enzo, 1:1,000); troponin I and phospho-TnI (S22/23) (Cell Signaling, 1:1,000 each).

Statistical Analysis
Data represent mean ± SE; group differences were tested for statistical significance using either ANOVA, followed by Bonferroni t-testing, or, when appropriate, Student’s t test (unpaired, 2-tailed). The null hypothesis was rejected when p < 0.05.

Results
AC6mut Transgenic Mice
AC6mut mice were physically indistinguishable from their transgene negative siblings. Necropsy of adult mice showed that body weight, tibial length, LV weight, and lung weight showed no group differences. (Table 1).

LV Expression of AC6mut. AC6mut mRNA was increased 62-fold and protein was increased 17-fold over the levels of endogenous AC6, which were detected using primers and antibody to the common regions on both endogenous AC6 and transgene AC6mut in RT-PCR and immunoblotting (Figs. 1B and 1C).

LV Expression of Endogenous AC Types. The mRNA of endogenous AC types 2–9 showed no group differences (data not shown).

LV cAMP Production. LV samples from AC6mut mice showed reduced cAMP production when stimulated with isoproterenol (74% reduction; p < 0.001) or NKH477, a water-soluble forskolin analog (52% reduction; p = 0.05) (Fig. 1D); basal cAMP production was unchanged. Thus, the transgenic line was suited to test the overall effect of reduced βAR-stimulated cAMP production in the presence of increased AC6mut expression on LV function.

PKA Activity and Expression. Cardiac myocytes isolated from AC6mut mice showed a 48% reduction in basal PKA activity (p = 0.01). In addition there were reductions in PKA activity stimulated by isoproterenol (38% reduction; p = 0.006) and NKH477 (38% reduction; p = 0.001) (Fig. 2A, upper). AC6mut

| Table 1. Body, LV, and Lung Weight. |
|-------------------------------------|
| **AC6mut (23)** | **TG- Control (16)** | **p** |
|-----------------|-----------------------|-------|
| Body (g)        | 25.5 ± 0.7            | 25.0 ± 1.2 | 0.7   |
| LV (mg)         | 91 ± 2.7              | 89 ± 3.4   | 0.6   |
| Tibial Length (mm) | 17 ± 0.1            | 16.7 ± 0.2 | 0.3   |
| LV/Lv (mg/g)    | 3.6 ± 0.1             | 3.6 ± 0.1  | 0.9   |
| LV/Tl (mg/mm)   | 5.4 ± 0.1             | 5.3 ± 0.2  | 0.7   |
| Lung (mg)       | 150 ± 4.9             | 149 ± 6.7  | 0.9   |
| Lung/Body (mg/g) | 6.0 ± 0.2             | 6.0 ± 0.2  | 0.9   |

LV, left ventricle; TL, tibial length. Values represent mean ± SE; Student’s t test (unpaired, 2-tailed).

do:10.1371/journal.pone.0072151.t001

Figure 2. Activities and Expression of PKA, PKS and PDE. A. PKA activity in isolated cardiac myocytes without stimulation (Basal) or stimulated with isoproterenol (Iso; 10 μM, 10 min) or NKH477 (NKH; 10 μM, 10 min). AC6mut expression reduced basal PKA activity (p = 0.01) and both Iso (p = 0.001) and NKH (p = 0.001) activities were reduced as well (n = 3, each group). B. The expression of key signaling proteins and their phosphorylation are shown in immunoblots using left ventricular homogenates from AC6mut and control mice. No group differences were observed. Shown are PKA catalytic unit, phospho (P) and Total (T) PKA regulatory subunits II-α and II-β, PKCα, phosphodiesterase type 3A (PDE3A), phospho-troponin I (P22/23-TnI), and total TnI. C. Phosphorylation of RyR2, PLB and TnI before and after isoproterenol stimulation was assessed in cardiac myocytes isolated from each group. Basal phosphorylation of RyR2, PLB and TnI showed no group differences. Isoproterenol stimulation was associated with increased phosphorylation of RyR2, PLB, and TnI in both groups, but was more extensive in cardiac myocytes from AC6mut mice. D. The data from Fig. 2C indicating that isoproterenol stimulation was associated with increased phosphorylation of RyR2, PLB, and TnI in cardiac myocytes from AC6mut mice are shown in graphic format, normalized for loading (GAPDH). The increase in TnI phosphorylation was not statistically significant (p = 0.07).
do:10.1371/journal.pone.0072151.g002

Handling to the Rescue
expression did not alter LV expression of the PKA catalytic subunit (Fig. 2B) or expression or phosphorylation of PKA-RII-α and β (phospho-PKA-RII): AC6mut, 0.32±0.04; Con, 0.30±0.03; p = 0.7; phospho-PKA-RIIβ: AC6mut, 7.1±1.1; Con, 10.6±0.1; p = 0.09 (Fig. 2B). PKC catalytic subunit expression also showed no group difference (PKCα: AC6mut, 0.8±0.1; Con, 0.7±0.1; p = 0.4; Fig. 2B).

**Isoproterenol-Stimulated Phosphorylation of Ryabonide Receptor-2, PLB, and Troponin I in Cardiac Myocytes.** Basal phosphorylation of RyR2, PLB and TnI showed no group differences (P-RyR2: AC6mut, 5.8±1.1 vs Con, 2.4±0.5; p = 0.06; P-PLB: AC6mut, 0.3±0.05 vs Con, 0.2±0.1; p = 0.8; P-TnI: AC6mut, 0.8±0.2 vs Con, 1.0±0.01; p = 0.24, Fig. 2C). Isoproterenol stimulation was associated with increased phosphorylation of RyR2, PLB, and TnI in both groups (vs unstimulated), but the extent of phosphorylation generally was greater in LV from AC6mut mice (P-RyR2: AC6mut, 30.0±1.1 vs Con, 7.4±2.1; p = 0.001; P-PLB: AC6mut, 16.8±2.4 vs Con, 5.3±0.1; p = 0.01; P-TnI: AC6mut, 5.8±2.1 vs Con, 2.2±0.7; p = 0.07; Fig. 2C). TnI protein expression was not different between groups (AC6mut, 0.9±0.1 vs Con, 0.7±0.2; p = 0.5; Fig. 2B). RyR2 mRNA expression showed no group difference (data not shown).

**PDE Activity and PDE3A Expression.** There was no group difference in PDE activity in LV samples (AC6mut: 1252±23 Units/mg, n = 7; Control: 1293±39 Units/mg, n = 6; p = 0.38). LV PDE3A protein expression showed no group difference (AC6mut: 0.3±0.1 vs Con, 0.4±0.1; p = 0.6; Fig. 2B).

**Intracellular Distribution of AC6mut.** AC6mut protein was identified in association with caveolae (mainly associated with plasma membrane), SR, and nuclear envelope (Fig. 1E).

**Echocardiography**

Echocardiography showed that basal cardiac structure and function were unchanged by cardiac-directed expression of AC6mut. LV dimensions were not different between groups, and basal LV ejection fraction and the velocity of circumferential fiber shortening were similar (Table 2). Thus, despite marked diminution of LV cAMP generating capacity in AC6mut mice, LV structure and basal function were unaltered.

**LV Contractile Function in Response to Isoproterenol**

To assess cardiac contractility in a manner independent of autonomic nervous influence, endogenous catecholamines, and anesthesia, LV pressure development was measured in isolated perfused hearts. Basal and isoproterenol-stimulated LV dP/dt showed no group differences (Fig. 3), despite marked diminution in LV cAMP generating capacity.

**Ca<sup>2+</sup> Uptake and Ca<sup>2+</sup> Related Proteins**

ATP-dependent SR Ca<sup>2+</sup> uptake rate in pooled LV homogenates from AC6mut and transgene-negative sibling control mice was determined. Increased AC6mut expression was associated with increased SR Ca<sup>2+</sup> uptake (Fig. 4A, upper panel). In addition, an increased affinity of SERCA2a for Ca<sup>2+</sup> was reflected in a reduced Ca<sup>2+</sup> concentration required for a half maximal effect (EC50: AC6mut 1.1 μmol/L; Control 3.7 μmol/L, n = 6, Fig. 4A, lower panel).

Associated with these physiological changes in Ca<sup>2+</sup> handling was altered LV expression of proteins that regulate SR Ca<sup>2+</sup> uptake. For example, AC6mut expression was associated with a 43% reduction in LV PLB protein expression (p = 0.01), and a 73% increase in LV S100A1 protein content (p = 0.03; Figs. 4B and 4C). The contents of LV SERCA2a, calreticulin, and calsequestrin were unchanged, and PLB phosphorylation at Ser16 was unchanged (Fig. 4D).

**Transcription Factors**

AC6mut expression was associated with a 2-fold increase in LV expression of CREM-1 (p = 0.03, Fig. 4B) and a 1.7-fold increase in phosphorylation of CREB at Ser133 (p = 0.01, Fig. 4C); total CREB protein content was unaltered. To determine whether increased CREM-1 and phospho-CREB were present in the nuclei, immunofluorescence staining of isolated cardiac myocytes was performed using anti-CREM-1 and anti-phospho-CREB (S133) antibodies. We detected increased nuclear localization of CREM-1 and phospho-CREB in AC6mut mice (Fig. 4E).

**Calcium Transients**

To determine whether increased SR Ca<sup>2+</sup> uptake associated with AC6mut expression would affect cytosolic [Ca<sup>2+</sup>]<sub>i</sub> cardiac myocyte real-time [Ca<sup>2+</sup>]<sub>i</sub> was assessed using the ratiometric dye Indo-1. Basal Ca<sup>2+</sup> release during contraction was unchanged (Fig. 5A). However, AC6mut expression was associated with increased peak systolic Ca<sup>2+</sup> transient amplitude after isoproterenol stimulation (p = 0.0001, Figs. 5B and 5C), and time to peak

---

**Table 2. Echocardiography (Basal).**

|            | AC6mut (8) | TG- Control (12) | p    |
|------------|------------|------------------|------|
| HR (bpm)   | 501±26     | 506±17           | 0.9  |
| EDD (mm)   | 4.2±0.2    | 4.3±0.1          | 0.7  |
| ESD (mm)   | 2.9±0.2    | 3.0±0.1          | 0.4  |
| PW Thickness (mm) | 0.6±0.1   | 0.6±0.1          | 0.5  |
| Septal Thickness (mm) | 0.6±0.1   | 0.6±0.1          | 0.4  |
| EDV (μL)   | 76±7       | 78±4             | 0.8  |
| ESV (μL)   | 25±4       | 27±2             | 0.6  |
| EF (%)     | 69±3       | 65±2             | 0.2  |
| CO (μL/min)| 26±2       | 26±2             | 0.8  |
| Vcf (circ/sec) | 7.0±0.7    | 6.2±0.3          | 0.2  |

---

**Figure 3. Left Ventricular Contractile Function.** Isolated hearts from AC6mut TG mice (closed circle; n = 11) showed preserved LV dP/dt in response to isoproterenol stimulation through a wide range of isoproterenol doses. Data were acquired and analyzed without knowledge of group identity. Open circles, transgene negative control mice (n = 12). There was no group difference (2-way ANOVA). Data points denote mean ±SE. doi:10.1371/journal.pone.0072151.g003
amplitude was decreased \((p = 0.03, \text{ Fig. 5D})\). In addition, time to 50\% relaxation (\(\tau\)) was decreased \((p = 0.04)\) in cardiac myocytes from AC6mut mice (Fig. 5E). Thus, SERCA2a activity, expression of PLB and S100A1, and isoproterenol-stimulated Ca\(^{2+}\) transients all were altered by AC6mut expression in a manner that would favorably influence LV function.

**Discussion**

The most surprising and important finding of this study is that cardiac-directed expression of a mutant AC6 molecule that markedly impairs bAR-stimulated cAMP production is associated with preserved LV function in response to isoproterenol stimula-

![Figure 4. SR Ca\(^{2+}\) uptake, Ca\(^{2+}\) signaling proteins, and transcriptional factors. A. Upper: Ca\(^{2+}\) uptake activity in pooled LV samples from AC6mut and TG negative sibling control mice (n = 6, both groups). Lower: Expression of AC6mut decreased SERCA2a affinity for Ca\(^{2+}\). The effective concentration of Ca\(^{2+}\) for 50\% maximal effect (EC\(_{50}\)) was calculated from the initial ATP-dependent Ca\(^{2+}\) uptake rate at different free Ca\(^{2+}\) concentrations. B. Upper: AC6mut expression was associated with decreased LV phospholamban (PLB) expression. Lower: AC6mut expression was associated with increased LV CREM-1 protein expression. C. Upper: AC6mut expression was associated with increased LV S100A1 protein expression. Lower: AC6mut expression was associated with increased LV P133-CREB protein phosphorylation. Total CREB expression was similar in both groups. D. AC6mut expression did not affect LV expression of SERCA2a, calreticulin, calsequestrin or phospho-S16-PLB proteins. (n = 4, both groups). E. Double immunofluorescence staining of AC6mut protein in isolated cardiac myocytes from AC6mut and control mice using anti-AU1 antibody (red) and anti-CREM-1 antibody (green) or anti-AU1 and anti-phospho-CREB (S133, green). Nucleus was showing in blue. AC6mut expression increased nuclear localizations of CREM-1 and phospho-CREB. In graphs (A,B,C), bars denote mean ±SE; numbers in bars indicate group size; members above bars indicate p values from Student’s t-test (unpaired, 2 tailed).

doi:10.1371/journal.pone.0072151.g004

![Figure 5. Cytosolic Ca\(^{2+}\) transients in isolated cardiac myocytes from AC6mut and control mice. A. Basal Ca\(^{2+}\) released (systolic-diastolic Ca\(^{2+}\)) showed no group difference. B. Representative Indo-1 Ca\(^{2+}\) transient recordings in cardiac myocytes stimulated with isoproterenol (Iso; 10 \(\mu\)M) were higher in cardiac myocytes from AC6mut mice. Summary data are displayed in Panel C. C. Ca\(^{2+}\) released in the presence of isoproterenol was increased in cardiac myocytes from AC6mut mice. D. Time-to-peak Ca\(^{2+}\) transient in the presence of isoproterenol was decreased in cardiac myocytes from AC6mut mice. E. Time to 50\% relaxation (\(\tau\)) in the presence of isoproterenol was decreased in cardiac myocytes from AC6mut mice. Experiments were repeated four times. Bars denote mean ±SE; numbers in bars indicate number of cardiac myocytes; numbers above bars indicate p values from Student’s t-test (unpaired, 2-tailed).

doi:10.1371/journal.pone.0072151.g005

PLOS ONE | www.plosone.org 6 September 2013 | Volume 8 | Issue 9 | e72151
tion. This was confirmed by echocardiography and studies of contractile function in isolated perfused hearts. Marked diminution of cardiac cAMP generation in other settings is associated with proportional reductions in LV contractile function. For example, most models of heart failure, where cAMP impairment typically is 50% reduced, there is a similar reduction in LV dP/dt and in βAR-responsiveness [10],[11],[12],[13],[14]. Furthermore, deletion of AC6, which is associated with a 60% reduction in cAMP generating capacity, was also associated with a similar reduction in LV contractile function [5]. What then explains preservation of isoproterenol-stimulated LV contractile function?

The proximate mechanisms for preserved LV function despite markedly impaired cAMP generation in the AC6mut line were favorable changes on Ca²⁺ handling. We previously reported that cardiac-directed expression of AC6 increased function of the failing heart, but because of pronounced effects of AC6 on βAR signaling, it was impossible to determine the degree to which these beneficial effects reflected augmented βAR signaling per se vs Ca²⁺ handling [10],[11]. Supporting the link of AC6 to Ca²⁺ handling is the observation that AC6 deletion has striking adverse effects on Ca²⁺ handling [5], but since cAMP-generating capacity was reduced following AC6 deletion, the independent effects of AC6 on Ca²⁺ handling were difficult to ascertain. What is new in the present study, however, is the demonstration in TG mice that an AC6 mutant molecule appears to mimic the parent molecule’s favorable effects on Ca²⁺ handling, thereby preserving LV function even whilst cAMP generating capacity is markedly diminished. It appears that the effects of AC6 on Ca²⁺ handling does not require cAMP generation, and must therefore occur through alternative mechanisms.

We found that AC6mut expression is associated with increased SR Ca²⁺ uptake in LV homogenates and increased Ca²⁺ transients with reduced time of relaxation in intact cardiac myocytes. Associated with these physiologically favorable effects of AC6mut expression was reduced PLB expression, a Ca²⁺ regulator that inhibits SERCA2a activity. Reduced PLB content or increased PLB phosphorylation at Ser16 is associated with reduction of its inhibitory effects, which increases SERCA2a activity [20],[21],[22]. We previously found that PLB expression is reduced in cultured cardiac myocytes expressing AC6 or AC6mut [4], but the current study is the first to demonstrate that this effect is also seen in vivo (Fig. 4B). Increases in the degree of isoproterenol-stimulated phosphorylation of RyR2, PLB, and to a lesser extent, TnI (Fig. 2C) in cardiac myocytes isolated from AC6mut mice would be predicted also to increase LV contractile function.

AC6mut expression was associated with increased expression and nuclear translocation of CREM-1 (Figs. 3B and 3E), a transcriptional suppressor in the CREB/ATF family [23]. We previously identified that, in the setting of AC6 expression, the PLB promoter was negatively regulated by increased ATF3 in neonatal rat cardiac myocytes through the CRE site in the PLB promoter [2]. In the present study we did not see increased ATF3 expression associated with AC6mut expression. However, both ATF3 and CREM-1 recognize the same CRE sites, so it is plausible that the AC6mut-related increased CREM-1 may be mechanistically important in reduced PLB expression. This will require additional study.

AC6mut expression was associated with an unanticipated increase in LV expression of the Ca²⁺ sensitizing protein, S100A1, which increases contractile function through modulation of RyR2 and SERCA2a [24]. How might AC6mut expression be linked with increased LV S100A1 expression? AC6mut expression was associated with increased phosphorylation and nuclear translocation of CREB (Figs. 4C and 4E), processes that are required for CREB activation. CREB is a transcriptional activator that regulates many genes through CRE site(s) in their promoters [25]. The S100A1 promoter possesses a CRE site [26], indicating that S100A1 expression could plausibly have been activated by AC6mut expression. In addition, compartmentalization of PKA and cAMP may also be factors [27],[28].

The substantial improvements in Ca²⁺ handling appear to have preserved LV function despite marked diminution in cAMP generation. The precise pathways by which increased amounts of AC6mut influence transcriptional regulation and ultimately the physiological behavior of cardiac myocytes and LV function will require additional studies. Histological studies (Fig. 1E) confirm that substantial amounts of transgene AC6mut are present in multiple intracellular compartments, not just in the plasma membrane. This enables AC6mut protein to interact with important intracellular proteins that influence intracellular signaling and thereby affect physiological function.

The importance of AC6 vis-à-vis Ca²⁺ handling was recently underscored by AC6 deletion [5]. In this setting, cAMP generating capacity was reduced, albeit not by as much as in the present study, but Ca²⁺ handling was markedly impaired. In the present study, we see more marked impairment of cAMP generation, but Ca²⁺ handling is increased, not decreased. This is because, unlike in AC6 deletion, the AC6 molecule, albeit one deficient in cAMP generating capacity, is present in the cytoplasm where it may influence Ca²⁺ handling.

A potential limitation of the present study is that we did not examine transgenic lines that expressed reduced amounts of AC6mut to determine if the physiological effects were proportional to level of AC6mut expression. One could argue that a 17-fold increase in AC6mut protein (vs endogenous AC6) might affect signaling in a non-specific manner. While our data cannot discount this possibility, it is important to recognize that endogenous AC6 is an exceedingly low abundance protein—approximately 100-fold less abundant, for example, than Gsζ [29]. Therefore, even expressed at 17-fold higher level than endogenous AC6, it still is considerably less abundant than Gsζ. Furthermore, similar increases in the catalytically active (normal) AC6 are associated with marked increases in recruitable cAMP production [30]. These observations suggest that the findings are specific.

Conclusions

Substantial improvements in Ca²⁺ handling appear to preserve LV function despite marked diminution in cAMP generation. Immunofluorescence indicates that AC6mut is located on the nuclear envelope, providing an opportunity for AC6mut to influence transcription factor expression and function. Increased CREM-1, a transcriptional suppressor and increased phospho-CRE (Fig. 4E) may be involved in altered expression of PLB and S100A1 respectively. We conclude that AC6mut preserves cardiac function through increased Ca²⁺ handling and altered protein expression, despite reduced cAMP generation. These results provide insight regarding the interplay between Ca²⁺ handling and βAR signaling vis-à-vis LV function, and indicate that AC6mut may provide inotropic stimulation free from the potentially deleterious effects of increased cAMP. It will be interesting to see what effects AC6mut expression has on the failing heart. Preliminary data indicate reduced cardiac myocyte apoptosis associated with AC6mut expression in the failing heart, which is a focus of an ongoing study in our laboratory.
Clinical perspective

So many clinical trials of positive isotopes have failed, that it is now axiomatic that agents which increase cAMP are deleterious to the failing heart. An alternative strategy is to alter myocardial Ca\(^{2+}\) handling or myofilament response to Ca\(^{2+}\) using agents that do not affect cAMP. Expression of a catalytically impaired AC6 mutant molecule — one that markedly reduces cAMP production — is associated with normal cardiac function in response to \(\beta\)-adrenergic receptor stimulation. The mechanism is through enhanced effects of AC6mut on Ca\(^{2+}\) handling — effects that do not require cAMP. These data are important in clinical settings for two reasons: 1) The results provide additional insight regarding the interplay between Ca\(^{2+}\) handling and \(\beta\)AR signaling vis-à-vis LV function; and 2) AC6mut may provide inotropic support free from the potentially deleterious effects of increased cAMP. Ongoing studies will be required to determine the effects of AC6mut gene transfer in the setting of heart failure.

Acknowledgments

We thank Matthew Spellman and Diane Huang for technical assistance.

Author Contributions

Conceived and designed the experiments: MHG NCL HKH. Performed the experiments: MHG NCL TG RT BJC HW NND JS. Analyzed the data: MHG NCL TT JS HKH. Contributed reagents/materials/analysis tools: TT WHD. Wrote the paper: MHG HKH.

References

1. Cleland JG, Terrell JK, Senior R, Nifontov EM, Mc Murray JJ, et al. (2011) The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 378: 676–683.
2. Gao MH, Tang T, Guo T, Sun SQ, Feramisco JR, et al. (2004) Adenylyl cyclase type VI gene transfer reduces phospholamban expression in cardiac myocytes via activating transcription factor 3. J Biol Chem 279: 38597–38602.
3. Gao MH, Tang T, Guo T, Yajima T, Petojanapam K, et al. (2008) Adenylyl cyclase type VI increases Akt activity and phospholamban phosphorylation in cardiac myocytes. J Biol Chem 283: 33537–33555.
4. Gao MH, Tang T, Lai NC, Yajima T, Miyahara A, et al. (2011) Beneficial effects of adenylyl cyclase type 6 (AC6) expression persist using a catalytically inactive AC6mut mutant. Mol Pharmacol 79: 381–388.
5. Tang T, Guo T, Lai NC, Farth Al., Takahashi T, et al. (2008) Adenylyl cyclase type 6 deletion decreases left ventricular function via impaired calcium handling. Circulation. 117: 61–69.
6. Ping P, Anzai T, Gao MH, Hammond HK (1996) Adenylyl cyclase and G protein receptor kinase expression during development of heart failure. Am J Physiol Heart Circ Physiol 273: H707–717.
7. Roth DM, Bayat H, Drumm JD, Gao MH, Swaney JS, et al. (2002) Adenylyl cyclase increases survival in cardiomyopathy. Circulation 105: 1899–1994.
8. Takahashi T, Tang T, Lai NC, Roth DM, Rebolloso B, et al. (2006) Increased cardiac adenylyl cyclase expression is associated with increased survival after myocardial infarction. Circulation 114: 388–396.
9. Lai NC, Roth DM, Gao MH, Tang T, Dalton N, et al. (2004) Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation 110: 350–356.
10. Roth DM, Gao MH, Lai NC, Drumm J, Dalton N, et al. (1999) Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circulation 99: 1099–1102.
11. Lai NC, Tang T, Gao MH, Saito M, Takahashi T, et al. (2008) Activation of cardiac AC6mut cyclase expression increases function of the failing ischemic heart in mice. J Am Coll Cardiol 51: 1490–1497.
12. Tang T, Gao MH, Roth DM, Guo T, Hammond HK (2004) Adenylyl cyclase type VI corrects cardiac sarcoplasmic reticulum calcium uptake defects in cardiomyopathy. Am J Physiol 287: H1906–1912.
13. Gaudin C, Ishikawa Y, Wight DC, Mahatria V, Nadal-Ginard B, et al. (1995) Overexpression of G\(\alpha\)q protein in the hearts of transgenic mice. J Clin Invest 95: 1676–1683.
14. Engelhardt S, Hein L, Wiesemann F, Lohse MJ (1999) Progressive hypertrophy and heart failure in \(\beta\)1-adrenergic receptor transgenic mice. Proc Natl Acad Sci 96: 7059–7064.
15. Liggett SB, Tepe NM, Lorenz JN, Canning AM, Jain TB, et al. (2000) Early and delayed consequences of \(\beta\)2-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 101: 1707–1714.
16. Antos CL, Frey N, Marx SO, Reiken S, Gaburjakova M, et al. (2001) Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ Res 89: 1007–1009.
17. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, Dibianco R, et al. (1991) Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325: 1460–1475.
18. Britrov MR, Ginsburg R, Minohe W, Cabaccioti RS, Sageman WS, et al. (1982) Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N Engl J Med 307: 205–211.
19. Suarez J, Scott B, Dillmann WH (2000) Conditional increase in SERCA2a protein is able to reverse contractile dysfunction and abnormal calcium flux in established diabetic cardiomyopathy. Am J Physiol 295: R1439–1445.
20. Brittsan AG, Kranias EG (2000) Phospholamban and cardiac contractile function. J Mol Cell Cardiol 32: 2131–2139.
21. Chu G, Lester JW, Young KB, Luo W, Zhou J, et al. (2000) A single site (Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to beta-agonists. J Biol Chem 275: 38938–38943.
22. Luo W, Chu G, Sato Y, Zhou Z, Kadambi VJ, et al. (1998) Transgenic approaches to define the functional role of dual site phospholamban phosphorylation. J Biol Chem 273: 4734–4739.
23. Foulines NS, Borrelli E, Sassone-Corsi P (1991) CREM gene: use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription. Cell 64: 739–749.
24. Most P, Remppis A, Pfeifer ST, Loeffle E, Ehlermann P, et al. (2003) Transgenic overexpression of the Ca\(^{2+}\)-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem 278: 33089–33017.
25. Mayr B, Montminy M (2001) Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2: 599–609.
26. Song W, Zimmer DB (1996) Expression of the rat S100A1 gene in neurons, glia, and skeletal muscle. Brain Res 721: 204–216.
27. Iancu RV, Ramanurthy G, Harvey RD (2000) Spatial and temporal aspects of cAMP signaling in cardiac myocytes. Clin Exp Pharmacol Physiol 35: 1343–1348.
28. Effenbury R, Samuelson BK, Nguyen BT, Phatparpek PV, Baumere F, et al. (2010) AKAP79 interacts with multiple adenylyl cyclase (AC) isoforms and scaffolds AC5 and AC6 to 9-aminio-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptors. J Biol Chem 285: 14450–14458.
29. Ostrom RS, Post SR, Insel PA (2000). Stoichiometry and compartmentation in glutamate-gated (AMPA) receptors. J Mol Neurosci 17: 199–212.
30. Gao MH, Lai NC, Roth DM, Zhou J, Zhu J, et al. (1999) Adenylylcyclase type VI gene transfer reduces phospholamban expression in cardiac myocytes. J Biol Chem 274: 17666–17672.
31. Efendiev R, Jakobsen MK, Nissen ML, Pedersen BS, Jakobsen TB, et al. (2008) AKAP79 interacts with multiple adenylyl cyclase (AC) isoforms and scaffolds AC5 and AC6 to 9-aminio-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptors. J Biol Chem 283: 14450–14458.
32. Gao MH, Lai NC, Roth DM, Zhou J, Zhu J, et al. (1999) Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice. Circulation 99:1618–1622.